简介：Objective:Toanalyzethecorrelationsamongcomorbidityandoverallsurvival(OS),biochemicalprogression-freesurvival(b-PFS)andtoxicityinelderlypatientswithlocalizedprostatecancertreatedwith125Ibrachytherapy.Methods:Elderlymen,aged≥65years,withlow-intermediateriskprostatecancer,weretreatedwithpermanent125Ibrachytherapyasmonotherapy.Comorbiditydatawereobtainedfrommedicalreportsusingage-adjustedCharlsoncomorbidityindex(a-CCI).Thepatientswerecategorizedintotwoagegroups(<75and≥75yearsold),andtwocomorbidityscoregroups(a-CCI≤3and>3).ToxicitywasscoredwithRadiationTherapyOncologyGroup(RTOG)scale.Results:FromJune2003toOctober2009,atotalof92elderlypatientsunderwentprostatebrachytherapy,including57men(62%)withlow-riskprostatecancer,and35men(38%)withintermediate-riskprostatecancer.Themedianageofpatientswas75years(range,65-87years).Forty-sevenpatients(51%)hada-CCI≤3and45patients(49%)a-CCI>3.Withamedianfollow-upperiodof56months(range,24-103months),the5-yearactuarialOSandb-PFSwere91.3%and92.4%respectively,withoutstatisticalsignificancebetweentwoCharlsonscoregroups.Toxicitywasmild.Noneofthepatientsexperiencedgastrointestinal(GI)toxicity,andonly4patiens(4%)experiencedlategenitourinary(GU)grade-3(G3)toxicity.NocorrelationbetweenacuteGUandGItoxicityandcomorbiditywasshowed(P=0.50andP=0.70,respectively).Conclusions:Ourdatasuggestthatelderlymenwithlow-intermediateriskprostatecancerandcomorbiditycanbeconsideredforaradicaltreatmentas125Ilow-doseratebrachytherapy.

简介：无